

LDN-212854

Catalog No: tcsc3212



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

1432597-26-6

Formula:

$C_{25}H_{22}N_6$

Pathway:

TGF-beta/Smad

Target:

TGF- β Receptor

Purity / Grade:

>98%

Solubility:

DMSO : \geq 30 mg/mL (73.80 mM)

Observed Molecular Weight:

406.48

Product Description


LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF- β type I receptors; possesses a bias towards ALK2(IC₅₀=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.

IC50 value: 1.3 nM [1]

Target: ALK2

In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity and function. LDN-212854 potently inhibits

heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!